Clinical trials: IPF
Idiopathic Pulmonary Fibrosis
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT04318704
- Testing
- Ifenprodil
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Algernon Pharmaceuticals
Healthy
Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects
A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects
- Trial name
- NCT05473533
- Testing
- PRS-220
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pieris Australia Pty Ltd
Idiopathic Pulmonary Fibrosis
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary…
- Trial name
- NCT04419558
- Testing
- Pamrevlumab
- Where
- 157 sites in United States, Argentina and 23 more
- Volunteers
- 372 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF).
- Trial name
- INFLO-2 (NCT07679893)
- Testing
- Nintedanib Dry Powder Inhalation
- Where
- Canada
- Volunteers
- 153 people
- Sponsor
- Mannkind Corporation
Idiopathic Pulmonary Fibrosis
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and…
- Trial name
- NCT02552849
- Testing
- No intervention
- Where
- 26 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
The primary objective of this study is to evaluate the effect of 52 weeks of once daily treatment with TPIP compared with placebo on lung function in adults with PPF.
- Trial name
- PALM-PPF (NCT07805785)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Volunteers
- 800 people
- Sponsor
- Insmed Incorporated
Progressive Pulmonary Fibrosis
Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis
This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
- Trial name
- PPF (NCT07503587)
- Testing
- HSK44459
- Volunteers
- 378 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Pulmonary Fibrosis
Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
Participation in the study will last for 3months, with a 1 month screening phase.
- Trial name
- NCT02510937
- Testing
- CC-90001
- Where
- 6 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Celgene
Fibrosis, Lung Disease
Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
The study is aimed to assess safety of Depelestat treatment, as well as efficacy on prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients suffering from persistent Acute Respiratory Distress…
- Conditions
- Fibrosis, Lung Disease, Respiratory Disorders, Respiratory Distress Syndrome, Adult
- Trial name
- NCT00455767
- Testing
- EPI-hNE4
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 84 people
- Sponsor
- Debiopharm International SA
Idiopathic Pulmonary Fibrosis
To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers
- Trial name
- NCT04888715
- Testing
- DWN12088, Pirfenidone, Nintedanib
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.